https://www.selleckchem.com/products/bms-986235.html 001), but aniseikonia did not change (P = 0.73). In patients with BRVO who had micropsia (≤ -2.0%) at baseline, mean aniseikonia significantly improved from -4.8 ± 3.3% to -0.9 ± 1.4% (P < 0.05). Aniseikonia after treatment significantly correlated with BCVA (P < 0.05) and the presence of SRD at baseline (P < 0.05). Majority of eyes with aniseikonia in BRVO had micropsia. The BCVA as well as the micropsia improved following treatment with IVR for BRVO. BCVA and the presence of SRD were predictors of post-treatment aniseikonia. Majority of eyes with aniseikonia in BRVO had micropsia. The BCVA as well as the micropsia improved following treatment with IVR for BRVO. BCVA and the presence of SRD were predictors of post-treatment aniseikonia. To describe a 3years experience of peripheral arterial embolization with Micro Vascular Plug (MVP) (Medtronic, USA). The following parameters were investigated type of vascular injury, anticoagulation therapy at time of procedure, anatomical district, caliper of the target artery, course of the landing zone, additional embolics, technical and clinical success, device related clinical complications. Technical success was defined as complete embolization without deployment of additional embolics after MVP release. Primary clinical success was considered as hemodynamic stability in emergency setting and resolution of the underlying vascular pathology in elective cases; secondary clinical success was considered clinical success after a second embolization session. 116 MVP have been released in 104 patients (67 males and 37 females; mean age 61.3years). The pullback release technique was adopted in each case. 85 patients were treated in emergent settings while in 19 patients the procedure was scheduled. The id not influence the technical outcome, straight course and length of the landing zone are essential parameters to evaluate before deployment. Herpes simplex diffuse endotheliitis w